# US 2017/0326252 A1 · Nanoparticles for Delivery of Agents to Glioblastoma Tumors > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2017/0326252 A1 - Document ID: US20170326252A1 - Status: Published application - Kind: A1 - Application number: 15/587,407 - Filed: 2017-05-05 - Published: 2017-11-16 - Earliest claimed: 2016-05-10 - Assignees: Nanoforma Inc. - Applicants: Nanoforma Inc. - Inventors: Amy Shuen - Web page: https://patentgrep.com/patent/US20170326252A1 ## CPC - A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle} - A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)} - A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65) - A61K 47/6901: {Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors} - A61K 47/6923: {the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb} - A61K 47/6925: {the form being a microcapsule, nanocapsule, microbubble or nanobubble} - A61K 51/1203: {in a form not provided for by groups A61K51/1206 - A61K51/1296, e.g. cells, cell fragments, viruses, virus capsides, ghosts, red blood cells, viral vectors} - A61K 51/1244: {microparticles or nanoparticles, e.g. polymeric nanoparticles} - A61K 51/1248: {nanotubes} - C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00) - B82Y 5/00: Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery - C12N 2770/00023: Virus like particles [VLP] - C12N 2770/00032: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent - C12N 2795/10122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) - C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00) - B82Y: SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES ## Abstract The present invention is, in general, directed to nanoparticles for the delivery of agents to glioblastoma tumors. More particularly, the present invention relates to nanoparticle conjugates that deliver and release agents to a glioblastoma tumor. The invention is also directed to methods of delivering agents to glioblastoma tumors. ## Claims ### Claim 1 A method for delivering an agent to a glioblastoma tumor, comprising the steps of: providing a nanoparticle wherein the nanoparticle is a cylinder having a diameter of about 5 to 20 nanometers and a length of about 10 to 100 nanometers, wherein the agent is conjugated to the nanoparticle; administering the nanoparticle agent conjugate to a subject wherein the glioblastoma tumor is located in a brain of the subject, and delivering the nanoparticle agent conjugate to the glioblastoma tumor. ### Claim 2 (depends on 1) The method of claim 1, wherein the nanoparticle is a viral nanoparticle. ### Claim 3 (depends on 1) The method of claim 1, wherein the nanoparticle further comprises a linker that conjugates the agent to the nanoparticle. ### Claim 4 (depends on 2) The method of claim 2, wherein the nanoparticle is a cylinder and has a diameter of 5 to 10 nanometers and a length of 25-50 nanometers. ### Claim 5 (depends on 3) The method of claim 3, wherein the linker is a cleavable linker, and further comprising the step of cleaving the linker to release the agent at the glioblastoma tumor. ### Claim 6 (depends on 5) The method of claim 5, wherein the linker comprises a peptide that can cleaved by a protease. ### Claim 7 (depends on 6) The method of claim 6, wherein the peptide comprises a valine linked to a citrulline by a peptide bond. ### Claim 8 (depends on 6) The method of claim 6, wherein the protease is a cathepsin B. ### Claim 9 (depends on 5) The method of claim 5, wherein the linker includes a self-immolative spacer. ### Claim 10 (depends on 1) The method of claim 1, wherein the agent is a reporter. ### Claim 11 (depends on 5) The method of claim 5, wherein the agent is selected from the group consisting of a mitotic inhibitor, an antitumor antibiotic, a plant alkaloid, an alkylating agent, an antimetabolite, and a radionuclide. ### Claim 12 (depends on 11) The method of claim 11, wherein the agent is a mitotic inhibitor. ### Claim 13 (depends on 11) The method of claim 11, wherein the agent is a plant alkaloid. ### Claim 14 (depends on 11) The method of claim 11, wherein the agent is an alkylating agent. ### Claim 15 A method for delivering an agent to a glioblastoma tumor, comprising the steps of: providing a viral nanoparticle wherein the viral nanoparticle is a cylinder having a diameter of about 5 to 20 nanometers and a length of about 10 to 100 nanometers, wherein the nanoparticle comprises a cleavable linker that conjugates the agent to the nanoparticle, administering the viral nanoparticle agent conjugate to a subject who has the glioblastoma tumor; and cleaving the linker to release the agent, whereby the viral nanoparticle agent conjugate delivers the agent to the glioblastoma tumor. ### Claim 16 (depends on 15) The method of claim 15, wherein the linker comprises a peptide that can cleaved by a protease. ### Claim 17 (depends on 16) The method of claim 16, wherein the protease is a cathepsin B. ### Claim 18 (depends on 15) The method of claim 15, wherein the agent is a reporter. ### Claim 19 (depends on 5) The method of claim 5, wherein the agent is selected from the group consisting of a mitotic inhibitor, an antitumor antibiotic, a plant alkaloid, an alkylating agent, an antimetabolite, and a radionuclide. ### Claim 20 (depends on 19) The method of claim 19, wherein the agent is an alkylating agent.